Cancer - OHE

Insight
June 2024

Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer

Insight
January 2024

Could Plant-based Diets Transform Health Care Spending?

Past Event
Commissioned Webinar
December 2023

Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?

Insight
March 2021

Time to Tackle the Challenges around Combination Therapies for Cancer

Insight
January 2021

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer

The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of achieving the WHO elimination target?

Could Plant-based Diets Transform Health Care Spending?

Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?

Time to Tackle the Challenges around Combination Therapies for Cancer

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

Making Outcome-Based Payment a Reality in the NHS

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Improving Efficiency and Resource Allocation in Future Cancer Care

The Expanding Value Footprint of Oncology Treatments

Share on Mastodon